Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0677930 (primary tumor)
 20,210 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Clinical features of 644 surgically treated cases of cancer of the uterine cervix were analyzed according to their histological type. Large cell non-keratinizing carcinomas (L) showed node metastasis proportional to the grade of invasion in the cervix, and the lowest recurrence rate. Small cell non-keratinizing carcinomas (S) tended to have widely spread metastasis from an early stage of the primary lesion. Lateral recurrence from metastatic foci was common in this type. Keratinizing carcinomas (K) were localized in the cervix until the primary tumor became enlarged to a certain size. Central recurrence from invasive foci in the surrounding tissue or organ occurred more often than lateral recurrence in this type. Metastasis pattern of pure adenocarcinomas (A) was similar to that of S, but recurrence was delayed. Adenosquamous carcinomas (AS) showed a similar metastasis pattern to that of K, but recurrence was rapid and the ratio high. Prophylactic maintenance chemotherapy with Tegafur (800 mg/day) or Carboquone (0.5 mg/day) was performed in 187 cases for a period of 2 years after surgery. The effect of maintenance chemotherapy depended on the histological type. A marked effect was obtained in the groups of S and A, in which no recurrence has appeared so far. The recurrence rate of L dropped to 1/5 that of the control. However, unsatisfactory results were shown in the groups of K and AS including the keratinizing cell component. It is of significance that maintenance chemotherapy showed the highest effectiveness in S and A on which conventional adjuvant therapy, i.e. postoperative radiotherapy, has had the least effect. This has led us to consider that a proper selection of adjuvant therapies would contribute toward improving the postoperative prognosis of patients with cancer of the uterine cervix.
 ...
PMID:[Differing progress patterns in cancer of the uterine cervix and variant effects of adjuvant chemotherapy based on histological type]. 308 Sep 62

The Lewis lung carcinoma, implanted in the footpad of BDF1 mice, was used for testing a preoperative chemotherapeutic treatment in comparison to a postoperative one, or to surgery alone. We administered both drugs effective in this model (Cyclophosphamide, Ifosfamide, CCNU), as well as ineffective ones (Ftorafur, Methyl-GAG, Vincristine) in order to study all the possible influences on the treatment outcome. In nine different experiments one active and one inactive drug were always compared in various schedules. Groups with surgery alone at an early or later stage were used as controls. The results showed that preoperative adjuvant treatment with an active drug decisively improved the survival time and the number of cured animals compared to surgery alone. The administration of an inactive drug and postponement of surgery decreased the number of cures, while the lifespan of the animals dying from lung metastases was not influenced. An improved treatment outcome compared to surgery alone resulted in cases where the preoperative inactive treatment was replaced by postoperative treatment with an active drug-a procedure also common and applicable for clinical practice. The body weight of the animals, noted as a sign of toxicity, was lowered when a cytostatic drug was used in addition to removal of the primary tumor. There was no difference between pre- or postoperative and repeated administrations. Based on these results preoperative adjuvant cytostatic treatment with histological control of response and decision for postoperative adjuvant treatment is recommended for clinical practice.
 ...
PMID:Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use. 359 36

Two cases of gastric cancer were treated with immunochemotherapy using Tegafur and Schizophyllan. In one case, a marked reduction in the size of metastatic liver tumor and disappearance of most subjective symptoms were observed. The response continued even 8 months after the initial treatment. In the other case, no marked symptoms except occasional dysphagis have been noted for 2 years and 2 months since diagnosis, although the primary tumor size has remained unchanged. Thus, it is presumed that the combined immunochemotherapy regimen may be useful in the treatment of advanced gastric cancer.
 ...
PMID:[Immunochemotherapy with tegafur and schizophyllan for stomach cancer--report of 2 cases]. 622 94

Between 1964 and 1981, seventy-two Japanese patients with gastric cancer associated with hepatic metastases, in whom the primary tumor had been resected, were treated in a nonrandomized manner at the Second Department of Surgery, Kyushu University Hospital. Fourteen received hepatic arterial infusion (HAI) of 5-FU and Mitomycin C (MMC) combined with systemic chemotherapy, 26 combination systemic chemotherapy of MMC, Futraful and PSK, 18 single drug (MMC) therapy, and 14 no chemotherapy. The average survival was 264 days in HAI combined with systemic chemotherapy, 208 in the combination systemic chemotherapy, 156 in the single drug therapy and 135 in those given no chemotherapy. One year survival and nine month survival rates were 21.4 per cent and 42.9 per cent in HAI combined with systemic chemotherapy, 11.5 per cent and 19.2 per cent in the combination systemic chemotherapy, 5.6 per cent and 11.1 per cent in the single drug therapy and 7.1 per cent and 14.3 per cent in the no chemotherapy group, respectively (HAI vs single drug therapy and no chemotherapy, p less than 0.01). Five of 14 patients treated with HAI combined with systemic chemotherapy showed a partial response (greater than 50 per cent reduction in tumor size), and the average survival time was 335 days, while that of nonresponders was 224 days. Six of 14 patients treated with combination infusion therapy with MMC and 5-FU survived 314 days, as compared to 201 days for patients with infusion of 5-FU alone.
 ...
PMID:Combination of hepatic arterial infusion and systemic chemotherapy for gastric cancer with synchronous hepatic metastases. 642 97

The main form of chemotherapy for non small cell lung cancer is a multiple combination therapy centered on cisplatin (CDDP). We herein report a case in which a favorable course was obtained for a patient with extremely rare AFP-producing lung cancer by single oral administrations of UFT, following extirpation of brain metastasis. The patient was an 80-year-old male whose main complaints were headache and aphasia. Following close examination, a diagnosis was made of moderately differentiated adenocarcinoma with the primary lesion in S6 of the right lung. A metastatic lesion was found in the left occipital lobe. Blood AFP was an abnormally high 17,000 ng/ml. No tumorous lesions were found in the liver. The brain metastasis were extirpated to alleviate cranial nerve symptoms, and the tissue was found to be the same as that of the primary lesion. AFP staining of the tumor tissue revealed positive cells. Because there was proliferation in the primary tumor following surgery, administration of UFT (300 mg/day Tegafur) was begun. Four weeks later the tumor had begun to shrink, and at 15 weeks was judged to be a partial response. A reduction in AFP was also seen. The patient showed absolutely no side effects from UFT, thus enabling outpatient treatment. Good results were obtained both in reducing the tumor and in maintaining the patient's quality of life.
 ...
PMID:[Effective treatment of AFP-producing lung cancer with UFT]. 1006 6